ACVR2B and prostate carcinoma: Of the 32 target hub genes, 4 were mapped to cell signalling pathways including ACVR1 and ACVR2B in TGF-beta signalling, CDKN1A and GSK3B in ErbB signalling (adj.P val = 0.016) and CDKN1A and GSK3B genes in Prostate cancer pathways (adj.